Pharmaceutical Market Europe • September 2025 • 3
COMMENT
In our cover story this month, Danny Buckland looks at how investing in data analytics and AI tools can lead to smarter clinical trials and faster, more informed decisions.
As Danny says: “The launch landscape is getting ever more complex and costly, but there are high expectations that innovative thinking and insightful strategies can be empowered and emboldened by data-driven technology and AI.
“The maths of a launch is sobering, with the latest Deloitte study, Measuring the Return from Pharmaceutical Innovation, reporting that the average cost of developing a drug has risen to $2.2bn in 2024, up from $2.1bn in 2023.
“Data and AI have established a clear value in research and drug discovery, but it is now time to focus on what they can do further along the commercial chain to reduce both risk and cost to promote return on investment.” Read more on page 26.
Also in this issue is an article looking at the impact of US tariffs on healthcare and life sciences multinationals, and the importance of ensuring business continuity across clinical, operational and commercial stages.
The authors from Baker McKenzie write: “As the life sciences industry grapples with the pressures of newly introduced ‘Most-Favored-Nation’ pricing requirements and evolving tariff structures, the industry faces mounting challenges that reverberate through pricing, access and supply chain management.
“The US and EU recently announced a 15% tariff ceiling on most imports, including pharmaceuticals (with exceptions for generics). [However], the US Section 232 national security investigation on imports of pharmaceuticals and active pharmaceutical ingredients is ongoing and may lead to higher tariffs in other regions.” Find out more on page 18.
Our next issue, in October 2025, will look at understanding the patient journey through stakeholder engagement to help improve patient pathways. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com.
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Deputy Editor
Emily Kimber
Studio:
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2025 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW